Search Results

You are looking at 1 - 2 of 2 items for :

  • Author or Editor: Alain P. Théon x
  • Pharmacology x
  • Refine by Access: All Content x
Clear All Modify Search


One hundred twenty cats with hyperthyroidism were treated with radioiodine (131I); 60 cats were administered radioiodine sc, and 60 cats were administered radioiodine iv. Before treatment, radioactive tracer studies were performed on each cat to determine peak radioactive iodine uptake and effective half-life. These data were used to calculate the dose of radioiodine that would have to be given to each cat to deliver 150 Gy to the thyroid tissue. The 2 groups of cats were similar with regard to age, tracer study results, and radioiodine dose. Mean estimated thyroid mass was larger for cats treated iv, but mean serum thyroxine concentration was higher for cats treated sc. Route of administration did not affect thyroidal uptake of radioiodine. However, radiation exposure of personnel was significantly lower with sc administration than with iv administration, even when iv catheterization was performed Eighty-five percent of cats treated iv and 84% of cats treated sc were euthyroid 4 years after treatment. Six percent of the cats became hypothyroid after treatment. When compared with iv administration, sc administration of radioiodine appeared to be as effective for treatment of hyperthyroidism, safer to personnel, and less stressful to the cats.

Free access
in American Journal of Veterinary Research



To develop a slow-release carboplatin formulation for intratumoral administration to cats.


Preliminary study to analyze pharmacokinetic effects of purified sesame oil in the carboplatin formulation for intratumoral administration, and a second study to evaluate the efficacy and toxicosis of intratumoral administration of carboplatin in purified sesame oil.


23 cats with squamous cell carcinomas of the nasal plane.


Eight cats with advanced-stage tumors were submitted to intratumoral administration of 100 mg of carboplatin/m2 of body surface area, with or without purified sesame oil, using a two-period, cross-over design. Fifteen additional cats were treated by intratumoral administration of carboplatin in purified sesame oil. Four weekly intratumoral chemotherapy injections of carboplatin in purified sesame oil at a dosage of 1.5 mg/cm3 of tissue were given.


Purified sesame oil in the formulation significantly reduced systemic exposure to carboplatin and drug leakage from the sites of injection. Cumulative effects of repeated intratumoral administrations on plasma concentrations of carboplatin were not observed. Systemic toxicosis was not observed, and local toxicosis was minimal. Healing of ulcerated lesions was not compromised. Rates of complete clinical tumor clearance and complete response were 67 and 73.3%, respectively. Product-limit estimates of mean progression-free survival times was 16 ± 3.3 months. The 1-year progression-free survival rate was 55.1 ± 13%. Local recurrence was observed in 7 cats; 4 had marginal tumor recurrence, and 3 had in-field and marginal tumor recurrence.


Intratumoral carboplatin chemotherapy is safe and effective for cats with squamous cell carcinoma of the nasal plane. Future studies to improve treatment efficacy could include evaluation of increased dose-intensity as well as combination of this modality with radiotherapy.

Clinical Relevance

Intratumoral administration of carboplatin in a water-sesame-oil emulsion was found to be a practical and effective new treatment for facial squamous cell carcinomas in cats.

Free access
in American Journal of Veterinary Research